Fabienne Laraque1, Heather A Mavronicolas, McKaylee M Robertson, Heidi W Gortakowski, Arpi S Terzian. 1. aDivision of Disease Control, New York City Department of Health and Mental Hygiene bFormerly of the HIV Care, Treatment and Housing Program, Bureau of HIV/AIDS Prevention and Control, New York City Department of Health and Mental Hygiene cVermont Department of Health, Burlington, Vermont dLong Island University, School of Health Professions, Brooklyn eHIV Care, Treatment and Housing Program, Bureau of HIV/AIDS Prevention and Control, New York City Department of Health and Mental Hygiene, New York, New York, USA.
Abstract
OBJECTIVE: HIV infection is a major problem in New York City (NYC), with more than 100,000 living HIV-infected persons. Novel public health approaches are needed to control the epidemic. The NYC Department of Health and Mental Hygiene (DOHMH) analysed community viral load (CVL) for a baseline to monitor the population-level impact of HIV control interventions. DESIGN: A cross-sectional study using routinely collected surveillance data. METHODS: All HIV-infected persons reported to the NYC HIV Registry who were at least 13 years of age, with at least one viral load test result in 2008, and alive at the end of 31 December 2008 were included. CVL was defined as the mean of individual viral load means reported between January and December 2008. Detectable viral load was defined as an individual mean of more than 400 copies/ml. Differences in CVL and proportion undetectable were computed by socio-demographic characteristics and summary measures were mapped. RESULTS: New York City CVL was 21,318 copies/ml overall (N=62,550) and 44,749 copies/ml (N=28,366) among persons with detectable mean viral loads. CVL varied by demographic and clinical characteristics, with statistically significant differences (P<0.001) in all groups except race/ethnicity (P=0.16). Men, persons aged 20-49 years, MSM, persons with AIDS, those with a CD4 cell count of 200 cells/μl or less and persons diagnosed after 2006 had higher mean viral load. Overall, 54.7% of HIV-infected persons had a suppressed mean viral load, with individual and neighbourhood variations (P<0.0001). CONCLUSION: This analysis showed strong disparities in reported CVL by individual characteristics and neighbourhoods. CVL patterns can be utilized to target interventions and track their impact.
OBJECTIVE:HIV infection is a major problem in New York City (NYC), with more than 100,000 living HIV-infectedpersons. Novel public health approaches are needed to control the epidemic. The NYC Department of Health and Mental Hygiene (DOHMH) analysed community viral load (CVL) for a baseline to monitor the population-level impact of HIV control interventions. DESIGN: A cross-sectional study using routinely collected surveillance data. METHODS: All HIV-infectedpersons reported to the NYC HIV Registry who were at least 13 years of age, with at least one viral load test result in 2008, and alive at the end of 31 December 2008 were included. CVL was defined as the mean of individual viral load means reported between January and December 2008. Detectable viral load was defined as an individual mean of more than 400 copies/ml. Differences in CVL and proportion undetectable were computed by socio-demographic characteristics and summary measures were mapped. RESULTS: New York City CVL was 21,318 copies/ml overall (N=62,550) and 44,749 copies/ml (N=28,366) among persons with detectable mean viral loads. CVL varied by demographic and clinical characteristics, with statistically significant differences (P<0.001) in all groups except race/ethnicity (P=0.16). Men, persons aged 20-49 years, MSM, persons with AIDS, those with a CD4 cell count of 200 cells/μl or less and persons diagnosed after 2006 had higher mean viral load. Overall, 54.7% of HIV-infectedpersons had a suppressed mean viral load, with individual and neighbourhood variations (P<0.0001). CONCLUSION: This analysis showed strong disparities in reported CVL by individual characteristics and neighbourhoods. CVL patterns can be utilized to target interventions and track their impact.
Authors: Ashly E Jordan; David C Perlman; Charles M Cleland; Katarzyna Wyka; Bruce R Schackman; Denis Nash Journal: J Clin Virol Date: 2020-01-27 Impact factor: 3.168
Authors: E J Edelman; J P Tate; D A Fiellin; S T Brown; K Bryant; N Gandhi; C L Gibert; M B Goetz; K S Gordon; M C Rodriguez-Barradas; R S Braithwaite; D Rimland; A C Justice Journal: HIV Med Date: 2015-02-17 Impact factor: 3.180
Authors: Ashly E Jordan; Charles M Cleland; Bruce R Schackman; Katarzyna Wyka; David C Perlman; Denis Nash Journal: J Infect Dis Date: 2020-09-02 Impact factor: 5.226
Authors: Ashly E Jordan; Charles M Cleland; Katarzyna Wyka; Bruce R Schackman; David C Perlman; Denis Nash Journal: J Infect Dis Date: 2020-09-02 Impact factor: 5.226
Authors: David M Moore; Zishan Cui; Nathan Lachowsky; Henry F Raymond; Eric Roth; Ashleigh Rich; Paul Sereda; Terry Howard; Willi McFarland; Allan Lal; Julio Montaner; Trevor Corneil; Robert S Hogg Journal: J Acquir Immune Defic Syndr Date: 2016-05-01 Impact factor: 3.731
Authors: Sheree R Schwartz; Matthew M Kavanagh; Jeremy Sugarman; Sunil S Solomon; Illiassou M Njindam; Kevin Rebe; Thomas C Quinn; Coumba Toure-Kane; Chris Beyrer; Stefan Baral Journal: J Int AIDS Soc Date: 2017-11 Impact factor: 5.396
Authors: Adam S Vaughan; Michael R Kramer; Hannah Lf Cooper; Eli S Rosenberg; Patrick S Sullivan Journal: J Med Internet Res Date: 2016-06-09 Impact factor: 5.428